This segment focuses on the development, commercialization, and ongoing research related to TAVNEOS (avacopan), an orally administered selective C5aR inhibitor, for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). Research and development activities include clinical trials to evaluate the efficacy and safety of avacopan in various patient populations and disease stages. The technology platform centers around small molecule drug development and targeted therapies for inflammatory diseases. The patient impact is significant, as TAVNEOS offers a novel treatment option for a rare and serious autoimmune disease, potentially improving patient outcomes and reducing the need for chronic steroid use. Market positioning is strong due to the unmet medical need and the innovative mechanism of action of avacopan. Future opportunities include expanding the use of avacopan in other complement-mediated diseases. Regulatory and clinical aspects involve ongoing post-marketing studies and interactions with regulatory agencies. Partnerships and collaborations are crucial for commercialization and further development of the drug.

This segment is dedicated to the research and development of novel cancer therapies, specifically focusing on CCX559, an orally administered inhibitor targeting the programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway. Research activities include preclinical studies, clinical trials, and the exploration of combination therapies to enhance efficacy. The segment utilizes advanced drug discovery techniques, including small molecule design and development, to create targeted cancer treatments. The therapeutic area encompasses various cancers, with the goal of improving patient outcomes through innovative immunotherapies. Market positioning is driven by the high unmet need in oncology and the potential of PD-1/PD-L1 inhibitors to revolutionize cancer treatment. Future opportunities include expanding the clinical development program and exploring partnerships to accelerate the development and commercialization of CCX559. Regulatory and clinical aspects involve navigating the complex regulatory landscape for oncology drugs and conducting rigorous clinical trials. The segment may collaborate with other pharmaceutical companies and research institutions to advance its oncology pipeline.

This segment focuses on the development of therapies for inflammatory bowel disease (IBD), with a primary focus on CCX507, an orally administered inhibitor of the chemokine receptor CCR9. Research and development activities include preclinical studies, clinical trials, and the evaluation of CCX507 in various IBD patient populations. The segment utilizes small molecule drug discovery and development technologies to create targeted therapies for IBD. The therapeutic area is focused on improving the treatment of Crohn's disease and ulcerative colitis. Patient impact is significant, as CCX507 aims to provide a new treatment option for patients with IBD, potentially improving their quality of life. Market positioning is based on the unmet medical need for effective IBD treatments and the potential of CCR9 inhibition to address inflammation in the gut. Future opportunities include expanding the clinical development program and exploring partnerships to accelerate the development and commercialization of CCX507. Regulatory and clinical aspects involve navigating the regulatory pathways for IBD drugs and conducting clinical trials to demonstrate efficacy and safety. The segment may collaborate with other pharmaceutical companies and research institutions to advance its IBD pipeline.